Donovan Hair Clinic, Whistler, BC, Canada.
Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
Skin Therapy Lett. 2023 May;28(3):1-7.
Oral Janus kinase (JAK) inhibitors now have a position as first-line agents for treating advanced alopecia areata. Oral JAK inhibitors are considerably more effective than topical JAK inhibitors, although topical agents may still have a valuable role for specific subgroups of patients. The US FDA approval of baricitinib in 2022 was an important milestone. Numerous JAK inhibitors are now being intensely studied for use in alopecia areata and several additional medications may also become approved in the near future. Accumulating clinical trial data points to a generally good safety profile for JAK inhibitors when used for patients with alopecia areata. However, long-term data pertaining to the safety and efficacy in this patient population are lacking.
口服 Janus 激酶（JAK）抑制剂现已成为治疗晚期斑秃的一线药物。口服 JAK 抑制剂比局部 JAK 抑制剂更有效，尽管局部药物对某些特定亚组患者仍可能具有重要作用。2022 年美国食品药品监督管理局批准巴瑞替尼是一个重要的里程碑。目前正在对许多 JAK 抑制剂进行深入研究，以用于治疗斑秃，并且在不久的将来可能会有更多的药物获得批准。越来越多的临床试验数据表明，JAK 抑制剂在治疗斑秃患者时具有良好的安全性。然而，针对该患者群体的安全性和疗效的长期数据仍缺乏。
